Alcoholic Hepatitis Network Observational Study

Status Recruiting

Clinical Trial Summary

The purpose of this research study is to create a clinical database and bio-repository. To do this, we will obtain blood, urine, saliva, and stool samples (e.g., biological samples) and personal health information from you to use in future research studies related to alcoholic hepatitis or other diseases. Part of your blood sample will be used to extract your DNA. DNA is the genetic material that gives us unique characteristics. We are doing this research study because we are trying to find out more about how and why illnesses related to alcoholic hepatitis or other diseases occur in people. To do this, we will study the biological samples and personal health information from healthy and sick people. A "biological sample" is usually blood, but can be any body fluid. "Personal Health Information" includes such items as your name, age, gender, race, and/or your medical information. It can also include data from measurements and tests that you had while participating in another research study or that were done during the course of your regular medical care or doctor visits.

Clinical Trial Description

What should I know about this research? - Someone will explain this research to you. - Taking part in this research is voluntary. Whether you take part is up to you. - If you don't take part, it won't be held against you. - You can take part now and later drop out, and it won't be held against you - If you don't understand, ask questions. - Ask all the questions you want before you decide. How long will I be in this research? We expect that your taking part in this research will last up to 6 months, after the 6 months we will look in your medical records every 180 days for up to five years. Why is this research being done? The purpose of this research is to create a clinical database and bio-repository to study alcoholic hepatitis. What happens to me if I agree to take part in this research? If you decide to take part in this research study, the general procedures include: 1) allowing the investigators to review your medical records, 2) answering questions about you and your health, 3) completing questionnaires about alcohol use, 4) having a physical exam and blood drawn, and 5) providing urine and stool samples. Could being in this research hurt me? The most important risks or discomforts that you may expect from taking part in this research include mild pain from blood draws and a small chance for a loss of confidentiality (e.g., unauthorized users gain access to sensitive and protected data about you). Will being in this research benefit me? It is not expected that you will personally benefit from this research. Possible benefits to others may include understanding specific health conditions in patients with alcoholic hepatitis or other diseases. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03850899
Study type	Observational
Source	Indiana University
Contact	Savannah Yarnelle
Phone	317-278-6424
Email	samussel@iu.edu
Status	Recruiting
Phase
Start date	April 17, 2019
Completion date	August 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04066179` - Efficacy of Monotherapy vs Combination Therapy of Corticosteroids With GCSF in Severe Alcoholic Hepatitis Patients.	N/A
Completed	`NCT03732586` - Effect of Omega 5 Fatty Acid as an Adyuvant Treatment to Prednisone in Patients With Severe Alcoholic Hepatitis	N/A
Completed	`NCT01476995` - Prognostic Indicators as Provided by the EPIC ClearView	N/A
Completed	`NCT00962442` - N-Acetylcysteine in Severe Acute Alcoholic Hepatitis	Phase 3
Not yet recruiting	`NCT06307522` - MRG-001 in Patients With Alcoholic Hepatitis	Phase 2
Recruiting	`NCT05018481` - HA35 Moderate Alcoholic Hepatitis (AH) Study	Early Phase 1
Completed	`NCT04544020` - Changes in gUt micRobiota After Enteral Feeding (in Alcoholic Hepatitis)
Recruiting	`NCT04088370` - Peripheral Blood Mononuclear Cells Response In Healthy Controls, Heavy Drinkers, and Patients With Alcoholic Hepatitis
Completed	`NCT04235855` - EUS Guided Liver Biopsy - Will it Give Better Yield, More Tissue With Less Complication?	N/A
Active, not recruiting	`NCT02344680` - Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
Completed	`NCT00851981` - Randomized, Controlled Trial of S-adenosylmethionine in Alcoholic Liver Disease	Phase 2
Completed	`NCT04084522` - Effect of Saturated Fat (Desi Ghee) on Gut-Liver Axis in Alcoholic Hepatitis	N/A
Completed	`NCT05840640` - Granulocyte Colony Stimulating Factor Four Week Plus N-Acetyl Cysteine in Severe Alcoholic Hepatitis	Phase 4
Recruiting	`NCT03069300` - N-ACetylcysteine to Reduce Infection and Mortality for Alcoholic Hepatitis	Phase 3
Terminated	`NCT02039219` - Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)	Phase 2
Completed	`NCT02019056` - Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis	Phase 2
Completed	`NCT01245257` - Effects of Prednisolone and Pentoxifylline on the Regulation of Urea Synthesis in Alcoholic Hepatitis	N/A
Completed	`NCT00388323` - Adipose Tissue Involvement in Alcohol-induced Liver Inflammation in Human	N/A
Recruiting	`NCT03845205` - Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH	N/A
Recruiting	`NCT03703674` - GCSF in Alcoholic Hepatitis	Phase 4